PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-36.98%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-26.05%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-129.84%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-151.38%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-173.20%
Negative net income growth while 4997.T stands at 26.21%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-173.27%
Negative EPS growth while 4997.T is at 13.68%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-173.27%
Negative diluted EPS growth while 4997.T is at 13.68%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.63%
Negative OCF growth while 4997.T is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-13.63%
Negative FCF growth while 4997.T is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
112.34%
Similar 10Y revenue/share CAGR to 4997.T's 112.31%. Walter Schloss might see both firms benefiting from the same long-term demand.
41.54%
5Y revenue/share CAGR under 50% of 4997.T's 85.84%. Michael Burry would suspect a significant competitive gap or product weakness.
10.69%
3Y revenue/share CAGR under 50% of 4997.T's 118.56%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.41%
Negative 10Y net income/share CAGR while 4997.T is at 395.80%. Joel Greenblatt sees a major red flag in long-term profit erosion.
48.41%
Below 50% of 4997.T's 1123.12%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-9.44%
Negative 3Y CAGR while 4997.T is 653.90%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
119.65%
10Y equity/share CAGR above 1.5x 4997.T's 69.13%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
36.70%
5Y equity/share CAGR above 1.5x 4997.T's 20.54%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
25.80%
3Y equity/share CAGR similar to 4997.T's 25.07%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.79%
Firm’s AR is declining while 4997.T shows 9.39%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
13.43%
Inventory growth well above 4997.T's 19.52%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-7.95%
Negative asset growth while 4997.T invests at 8.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
3.07%
50-75% of 4997.T's 5.84%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-4.40%
We’re deleveraging while 4997.T stands at 3.04%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-18.67%
Our R&D shrinks while 4997.T invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
19.64%
SG&A growth of 19.64% while 4997.T is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.